DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Haloperidol vs Conventional Therapy for Gastroparesis

Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gastroparesis

Intervention: Haloperidol (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: The University of Texas Health Science Center, Houston

Official(s) and/or principal investigator(s):
Carlos J Roldan, MD, Principal Investigator, Affiliation: University of Texas

Overall contact:
Carlos J Roldan, MD, Email: Carlos.J.Roldan@uth.tmc.edu

Summary

Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.

Clinical Details

Official title: Haloperidol vs Conventional Therapy for Gastroparesis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Symptoms relief - defined as improvement on mean change in Liker pain scale 1-5

Secondary outcome: Time frame for discharge

Detailed description: Study Design This study is a prospective, double-blind randomized placebo controlled trial involving adult emergency department (ED) patients who present with an acute exacerbation of gastroparesis. This study design will have two arms in the clinical trials. An experimental arm will receive an intravenous dose of haloperidol 5 mg in addition to conventional therapy, and the control arm will receive conventional therapy. Patients will be randomized as described below. Neither the physician nor the patient will be aware of the group to which the patient was randomized. Methods Upon arrive at to the ED at the Memorial Hermann Hospital located in the Texas Medical Center; patients with gastroparesis (GP) exacerbation will be assessed for eligibility for enrollment in this trial by the clinicians on duty. Informed consent will be obtained from eligible patients that meet inclusion and exclusion criteria by trained ED residents. A 12 lead electrocardiogram will be performed to evaluate the presence of QT segment prolongation. Enrolled patients will be given 5 mg of intravenous haloperidol or equivalent volume of placebo pre-packaged and coded with a study ID number provided by the investigational pharmacy. No unique identifiers or other PHI will be collected on enrolled patients. Information will also be recorded on the time elapsed from the time it took to provide the study medication and the time of the decision on disposition (admit or discharge). A record will be maintained if any additional medications including analgesics and antiemetics given to the patient before and after the study vial are given. Data will be collected on any adverse effects or complications the patients may experience (i. e. dystonic reactions, allergies etc.). After the data is collected at one hour for the primary outcome the trial will end and the physician will be unblended so they can choose subsequent medication. All completed data collection forms will be dropped off in a secure locked mailbox and collected on a weekly basis by research staff. Collected forms will be housed in the ED office located in the Jesse Jones Library (JJL) 4th floor in a locked cabinet. Data will be entered electronically and analyzed using statistical package for the social sciences (SPSS) version 19. 0. This database will be housed on a rights-protected research drive with limited access for viewing. Informed Consent Patients will be notified of this study and they will be asked if they are interested in participating. If they are interested in participating, they will have the informed consent (IC) explained to them in either English or Spanish (Beaudoin, Nagdev, Merchant & Becker, 2010). The patient will sign, date, and put the time on the IC. The consenter will also do the same. A copy of the IC will be made in the ED and given to the patient for their records. The original copy will be housed in the regulatory binder located in JJL.

Eligibility

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Previous diagnosis of GP including those without formal gastric emptying studies.

- Patients presenting with unresolving nausea, vomiting, and abdominal pain that is

attributable to their GP. Exclusion Criteria:

- History of QT prolongation or presence on a 12 leads electrocardiogram.

- Presence of concomitant acute abdominal pathology including but not limited to

hepatobiliary disease, ischemia, and abdominal aneurysm.

- Prisoners

- Hypotension (systolic blood pressure below 90 mm Hg)

- Pregnant women

- Patients who are cognitively impaired and/or unable to consent for the study

- Age <18

- Allergy to haloperidol

Locations and Contacts

Carlos J Roldan, MD, Email: Carlos.J.Roldan@uth.tmc.edu

Lyndon Baines Johnson General Hospital, Houston, Texas 77026, United States; Recruiting
Carlos J Roldan, MD, Email: Carlos.J.Roldan@uth.tmc.edu
Carlos J Roldan, MD, Principal Investigator
Yashwant Chathampally, MD, Principal Investigator
Linda Paniagua, MD, Sub-Investigator
Peter J Carlson, MD, Sub-Investigator
Sonali Patel, MD, Sub-Investigator
Additional Information

Starting date: November 2012
Last updated: June 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017